Document is current
Any future updates will be listed below
-
Authors
Madden, Daniel W.
Sunwoo, Sun-Young
Gaudreault, Natasha N.
Trujillo, Jessie D.
Morozov, Igor
Gallardo, Carmina
Richt, Juergen A. https://orcid.org/0000-0001-7308-5672
-
Funding
Funding for this research was provided by:
the National Bio and Agro-Defense Facility (NBAF) Transition Fund from the State of Kansas
AMP Core of the Center of Emerging and Zoonotic Infectious Diseases (CEZID) from National Institute of General Medical Sciences (P20GM130448)
- License Information
-
More Information
Article History
Received: 17 March 2022
Accepted: 12 May 2022
First Online: 21 June 2022
Declarations
:
: Experiments involving live animals were approved by the Kansas State University Institutional Biosafety Committee (IBC, protocol #: 850, 1049, 1397) and Institutional Animal Care and Use Committee (IACUC, Protocol #: 3513, 3758, 4363).
: Not applicable.
: JAR, IM, DWM, SYS are inventors on patents and patent applications on the use of antivirals, diagnostics and vaccines for the treatment and prevention of virus infections, owned by Kansas State University. The use of the p30 monoclonal antibodies was licensed to Silver Lake Research Corporation, Irwindale, CA, USA, and the product is commercially available as PenCheck® (). JDT, NNG, and CG have no competing interests. Jurgen A. richt was not involved in the journal’s review or decisions related to this manuscript.
